November 09, 2015 (Shareholders Foundation) - An investigation on behalf of investors of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares over potential securities laws violations by Vertex Pharmaceuticals and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) concerning whether a series of statements by Vertex Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Vertex Pharmaceuticals Incorporated that its annual Total Revenue declined from over $1.52 billion in 2012 to $580.41 million in 2014 and that its Net Income of $32.27 million in 2012 declined to a Net Loss of $737.64 million in 2014

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) grew from $26.60 per share in November 2011 to as high as $141.48 per share on August 19, 2015.

On October 30, 2015, Vertex Pharmaceuticals Incorporated disclosed receipt of a subpoena from the U.S. Department of Justice, seeking information 'relating primarily to [the company's] Good Laboratory Practices in a bioanalytical laboratory.'

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) closed on November 6, 2015, at $117.96 per share.